Octanoylated ghrelin binds high-affinity hypothalamic and pituitary receptors displaced by MK-0677 and hexarelin
Background
Growth hormone (GH) deficiency and dysregulated GH secretion involve complex hypothalamo-pituitary signaling. The GHS-R (GH secretagogue receptor) was long an orphan receptor activated by synthetic peptidyl GHS such as hexarelin and non-peptidyl GHS such as MK-0677 to potently stimulate GH release. Ghrelin was subsequently proposed as the endogenous natural ligand for GHS-R, but direct binding evidence in human hypothalamic and pituitary tissue was lacking. Understanding which molecular forms of ghrelin actually engage these receptors — and whether synthetic GHS share the same binding sites in humans — is essential for interpreting clinical GH-secretagogue pharmacology and for validating ghrelin-based therapeutic strategies.
Study Design
Researchers performed radioligand saturation binding analysis using 125I-labeled human ghrelin applied to membrane preparations from human hypothalamus and pituitary gland. Competition binding assays tested the ability of multiple compounds — including octanoylated ghrelin, desoctanoylated ghrelin, hexarelin, MK-0677, the GHS antagonists EP-80317 and [D-Arg1-D-Phe5-D-Trp7,9-Leu11]-substance P, somatostatin (SRIH-14), GHRH-44, and SRIH analogs vapreotide and cortistatin-14 — to displace the radioligand. The primary endpoints were maximal binding capacity (Bmax) and dissociation constant (Kd) in each tissue.
Results
Saturation binding analysis revealed a single class of high-affinity binding sites with limited binding capacity in both human hypothalamus and pituitary gland. Bmax values were significantly greater in the hypothalamus than in the pituitary (p < 0.001), while Kd values were similar between the two tissues, indicating comparable receptor affinity but higher receptor density hypothalamically. Displacement of 125I-ghrelin from hypothalamic membranes was achieved by octanoylated ghrelin, hexarelin, MK-0677, GHS antagonists EP-80317 and [D-Arg1-D-Phe5-D-Trp7,9-Leu11]-substance P, and the SRIH analogs vapreotide and cortistatin-14. Notably, native SRIH-14, GHRH-44, and desoctanoylated ghrelin showed no competition with the radioligand whatsoever.
The octanoyl modification of ghrelin is strictly required for receptor binding; the desoctanoylated precursor form — despite being a closely related peptide — is entirely devoid of binding activity at hypothalamo-pituitary
GHS-Rsites.
Key Findings
- Single class of high-affinity
GHS-Rbinding sites identified in both human hypothalamus and pituitary by saturation analysis. - Hypothalamic Bmax significantly greater than pituitary Bmax (p < 0.001); Kd values similar between tissues.
- MK-0677, hexarelin, EP-80317, vapreotide, and cortistatin-14 all displaced 125I-ghrelin from hypothalamic membranes.
- Desoctanoylated ghrelin, native SRIH-14, and GHRH-44 showed zero competition with the radioligand.
- Octanoylation is strictly required for ghrelin to bind its hypothalamo-pituitary receptors.
Why It Matters
The octanoyl fatty-acid modification on ghrelin is non-negotiable for receptor engagement, directly validating why unacylated ghrelin fragments lack GH-releasing potency. For clinicians and researchers, this confirms that MK-0677 (ibutamoren) and hexarelin compete for the identical high-affinity binding site as endogenous ghrelin in human brain and pituitary tissue — a pharmacologically critical finding. The discovery that SRIH analogs vapreotide and cortistatin-14 — but not native SRIH-14 — bind the same sites adds a layer of complexity to combination somatostatin/GHS protocols and raises questions about receptor cross-talk. Hypothalamic receptor density substantially exceeds pituitary density, suggesting the hypothalamus may be the primary site for GHS action and that central GHS-R targeting deserves priority in therapeutic design.
TitrateLab articles covering MK-677
Written by TitrateLab, separately from the study summarized above.
